Curanex Pharmaceuticals (CURX) Interest Expenses (2024 - 2025)

Curanex Pharmaceuticals' (CURX) quarterly Interest Expenses came in at $241918.0 in Q3 2025, up 40.94% on a QoQ basis from $171652.0 in Q2 2025.

Curanex Pharmaceuticals (CURX) Interest Expenses (2024 - 2025) Analysis & Trends

Curanex Pharmaceuticals (CURX) has 2 years of Interest Expenses data on file, last reported at $241918.0 in Q3 2025.

Quarterly Interest Expenses changed N/A year-over-year to $241918.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $241918.0 (changed N/A YoY) and the FY2025 annual result came in at $1.0 million, up 682.06% from the prior year.
Interest Expenses advanced to $241918.0 in Q3 2025, from $171652.0 in the prior quarter.
In the past five years, Interest Expenses ranged from a high of $241918.0 in Q3 2025 to a low of $130087.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	11.00 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	39.74 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	82.05 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-4.89 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	20.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	93.62 Mn
10	Curanex Pharmaceuticals	6.02 Mn	1.02 Mn	-	-

Download Data